GlaxoSmithKline, Vir Biotechnology Expand Monoclonal Antibody Pact
GlaxoSmithKline (GSK) and Vir Biotechnology have teamed up to develop monoclonal antibodies for respiratory viruses, building off an existing agreement struck last year to develop COVID-19 therapies.
As part of the deal, GSK will co-develop Vir’s intramuscular influenza prophylactic, VIR-2482, which is currently being evaluated in a phase 2 trial. The drugmakers will also develop up to three non-coronavirus or influenza antibodies during a three-year research period, leveraging GSK’s small molecule compounds and Vir’s monoclonal antibody platform.
GSK said it will pay $225 million up front and make a $120 million equity investment in Vir. It also could pay an additional $500 million in development options.